NCT05643651View on ClinicalTrials.gov

Rivaroxaban for Children Aged Over 2 Years With Giant Coronary Artery Aneurysms After Kawasaki Disease

PHASE4RecruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

June 1, 2025

Primary Completion Date

June 1, 2027

Study Completion Date

September 1, 2027

Conditions
Kawasaki DiseaseCoronary Artery Aneurysm
Interventions
DRUG

Rivaroxaban Oral Tablet [Xarelto]

Administered in an age- and bodyweight-adjusted, 15 mg-equivalent dose regimen proposed by model- and clinical evidence-informed precision dosing

DRUG

Aspirin or Clopidogrel

Aspirin \[3 \~5mg/(kg·d) once daily\] or Clopidogrel \[1.0 mg/kg; once daily\]

DRUG

Warfarin

Warfarin 0.05\~0.12 mg/(kg·d) once daily. INR should maintain within 1.5 to 2.5

Trial Locations (1)

201102

RECRUITING

Children's Hospital of Fudan University, Shanghai

All Listed Sponsors
lead

Children's Hospital of Fudan University

OTHER